Investing.com -- Bank of America upgraded Moderna to Neutral with a $170 price objective, following a sharp rally in the stock after positive data on its personalized cancer vaccine, intismeran, in adjuvant melanoma.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
78last 24h
979last 7d
110● bullish (7d)
126● bearish (7d)
212publishers
Investing.com30d agobullish
BofA upgrades Moderna after 177% rally driven by cancer vaccine breakthroughGuruFocus.com31d agobearish
Intel Stock Plunges 7% as UBS Cuts Price Target to $112Intel Stock Takes Another Hit as UBS Trims Price Target to $112